Previous 10 | Next 10 |
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory r...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disea...
Arcturus Therapeutics ( NASDAQ: ARCT ) said on Wednesday it had obtained an award for up to $63.2M from the Biomedical Advanced Research and Development Authority. ( ARCT ) rose ~6% after the bell. The award will be provided over three years to support prec...
Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to f...
New clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Six months after booster dose of ARCT-154: BA.1: GMFR = 22 to 52; Titer = 674 to 1524 BA.2: GMFR = 25 to 55; ...
Raymond James has downgraded Arcturus Therapeutics ( NASDAQ: ARCT ) to underperform from market perform citing setbacks for vaccines for COVID-19, ornithine transcarbamylase deficiency, and cystic fibrosis. The firm does not have a price target. Analyst Steven Seedhous...
Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientifc Officer and Chief O...
Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q2 GAAP EPS of -$0.82 beats by $1.04 . Revenue of $27.09M (+1254.5% Y/Y) beats by $24.58M . Company’s cash balance totaled $283.5 million as of June 30, 2022, compared to a cash balance of $370.5 mill...
New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 at Day 91 New cold chain data for Arcturus’ lyophilized vaccine platform shows favorable stability, shipping, a...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...